Racial differences in neuromyelitis optica spectrum disorder

被引:132
|
作者
Kim, Su-Hyun [1 ]
Mealy, Maureen A. [3 ]
Levy, Michael [3 ]
Schmidt, Felix [4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Ruprecht, Klemens [5 ]
Paul, Friedemann [4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Ringelstein, Marius [11 ]
Aktas, Orhan [11 ]
Hartung, Hans-Peter [11 ]
Asgari, Nasrin [12 ,13 ]
Tsz-Ching, Jessica Li [14 ]
Siritho, Sasitorn [15 ]
Prayoonwiwat, Naraporn [15 ]
Shin, Hyun-June [1 ]
Hyun, Jae-Won [1 ]
Han, Mira [2 ]
Leite, Maria Isabel [16 ]
Palace, Jacqueline [16 ]
Kim, Ho Jin [1 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Dept Neurol, Goyang, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Biometr Res Branch, Goyang, South Korea
[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[4] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany
[5] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[6] Free Univ Berlin, Berlin, Germany
[7] Humboldt Univ, Berlin, Germany
[8] Berlin Inst Hlth, Berlin, Germany
[9] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany
[10] Charite Univ Med Berlin, Berlin, Germany
[11] Heinrich Heine Univ, Dept Neurol, Med Fac, Dusseldorf, Germany
[12] Univ Southern Denmark, Dept Neurol, Slagelse Hosp, Odense, Denmark
[13] Univ Southern Denmark, Inst Reg Hlth Res & Mol Med, Odense, Denmark
[14] Queen Elizabeth Hosp, Dept Neurol, Hong Kong, Peoples R China
[15] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand
[16] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England
关键词
CLINICAL CHARACTERISTICS; MULTICENTER; AQUAPORIN-4; FEATURES; COHORT; EPIDEMIOLOGY; ASSOCIATION; ANTIBODIES; MYELITIS; NMO;
D O I
10.1212/WNL.0000000000006574
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective We aimed to evaluate racial differences in the clinical features of neuromyelitis optica spectrum disorder. Methods This retrospective review included 603 patients (304 Asian, 207 Caucasian, and 92 Afro-American/Afro-European), who were seropositive for anti-aquaporin-4 antibody, from 6 centers in Denmark, Germany, South Korea, United Kingdom, United States, and Thailand. Results Median disease duration at last follow-up was 8 years (range 0.3-38.4 years). Asian and Afro-American/Afro-European patients had a younger onset age than Caucasian patients (mean 36, 33, and 44 years, respectively; p < 0.001). During the disease course, Caucasian patients (23%) had a lower incidence of brain/brainstem involvement than Asian (42%) and Afro-American/Afro-European patients (38%) (p < 0.001). Severe attacks (visual acuity <= 0.1 in at least one eye or Expanded Disability Status Scale score >= 6.0 at nadir) at onset occurred more frequently in Afro-American/Afro-European (58%) than in Asian (46%) and Caucasian (38%) patients (p = 0.005). In the multivariable analysis, older age at onset, higher number of attacks before and after immunosuppressive treatment, but not race, were independent predictors of severe motor disabilities at last follow-up. Conclusion A review of a large international cohort revealed that race affected the clinical phenotype, age at onset, and severity of attacks, but the overall outcome was most dependent on early and effective immunosuppressive treatment.
引用
收藏
页码:E2089 / E2099
页数:11
相关论文
共 50 条
  • [31] Neuromyelitis Optica Spectrum Disorder: A Case Report
    Yaregal, Samson
    Bekele, Nebiyu
    Gebrewold, Yonathan
    Tadesse, Abilo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2021, 14 : 643 - 648
  • [32] Membranous nephropathy with Neuromyelitis optica spectrum disorder
    Li, Xiangling
    Wang, YanQiang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 15 : 49 - 51
  • [33] Controversies in the management of neuromyelitis optica spectrum disorder
    Bruscolini, Alice
    La Cava, Maurizio
    Mallone, Fabiana
    Marcelli, Michela
    Ralli, Massimo
    Sagnelli, Paolo
    Greco, Antonio
    Lambiase, Alessandro
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (11) : 1127 - 1133
  • [34] Frequency of comorbidities in neuromyelitis optica spectrum disorder
    Barzegar, M.
    Mirmosayyeb, O.
    Nehzat, N.
    Vaheb, S.
    Shaygannejad, V.
    Asgari, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 460 - 460
  • [35] Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
    Yamamura, Takashi
    Kleiter, Ingo
    Fujihara, Kazuo
    Palace, Jacqueline
    Greenberg, Benjamin
    Zakrzewska-Pniewska, Beata
    Patti, Francesco
    Tsai, Ching-Piao
    Saiz, Albert
    Yamazaki, Hayato
    Kawata, Yuichi
    Wright, Padraig
    De Seze, Jerome
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (22): : 2114 - 2124
  • [36] Depression in patients with neuromyelitis optica spectrum disorder
    Seok, J. M.
    Choi, M.
    Kim, Y. S.
    Cho, E. B.
    Lee, H. L.
    Kang, S. -Y.
    Lee, K. H.
    Kim, B. J.
    Min, J. -H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 94 - 94
  • [37] Hypogeusia as a symptom of neuromyelitis optica spectrum disorder
    Iones, Anna
    Howard, Jonathan
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1548 - 1549
  • [38] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Tina Nie
    Hannah A. Blair
    CNS Drugs, 2022, 36 : 1133 - 1141
  • [39] Choreoathetosis in a patient with neuromyelitis optica spectrum disorder
    Sugeno, Naoto
    Izumi, Rumiko
    Kato, Kazuhiro
    Nakashima, Ichiro
    Takeda, Atsushi
    Aoki, Masashi
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2013, 1 (04): : 154 - 156
  • [40] Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Nie, Tina
    Blair, Hannah A.
    CNS DRUGS, 2022, 36 (10) : 1133 - 1141